Explore the exciting world of NovoCure (NVCR -2.97%) with our expert analysts in this Motley Fool Scoreboard episode. Check out the video below to gain valuable insights into market trends and potential investment opportunities!
*Stock prices used were the prices of Jan. 29, 2025. The video was published on Mar. 4, 2025.
Free Article
You're reading a free article with opinions that may differ from The Motley Fool's Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More
Karl Thiel has positions in NovoCure. Keith Speights has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends NovoCure. The Motley Fool has a disclosure policy.
Stocks Mentioned
NovoCure
NVCR
$16.48
(-2.97%)
$0.51
*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.
Related Articles
NovoCure Q4 EPS Misses, Revenue Matches
Why Novocure Stock Was Winning Big This Week
Novocure Has Already Doubled in 2024. Can It Soar Higher in 2025?
NovoCure Beats Q3 Revenue, EPS Estimates
Why NovoCure Stock Dived by 13% This Week
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.